Keloid scarring, but not dupuytren's contracture, is associated with unexplained carotid atherosclerosis

Clinical and Investigative Medicine

Volumn 32, Issue 2, 2009, Pages

  Bhavsar, Sankalp ^a   Nimigan, Andre ^b   Hackam, Daniel G ^c   O'Gorman, David B ^b,d   Gan, Bing Siang ^b,d   David Spence, J ^b,d,e  

^a WESTERN UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^e Stroke Prevention and Atherosclerosis Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DUPUYTREN CONTRACTURE; FEMALE; HUMAN; KELOID; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; CAROTID ARTERY DISEASES; DUPUYTREN'S CONTRACTURE; FEMALE; HUMANS; KELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 65249134044     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. van dM, I, Iglesias del SA, Hak AE, Bots ML, Hofman A, Witteman JC. Risk factors for progression of atherosclerosis measured at multiple sites in the arterial tree: the Rotterdam Study. Stroke 2003;34:2374-9.
2. Espeland MA, Tang R, Terry JG, Davis DH, Mercuri M, Crouse JR, III. Associations of risk factors with segment-specific intimal-medial thickness of the extracranial carotid artery. Stroke 1999;30:1047-55.
3. Kannel WB. Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure. Cardiovasc Drugs Ther 1997;11 Suppl 1:199-212.
4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulatio. 1998;97:1837-47.
5. Spence JD, Barnett PA, Bulman DE, Hegele RA. An approach to ascertain probands with a non traditional risk factor for carotid atherosclerosis. Atherosclerosis 1999;144:429-34.
6. Spence JD. Technology Insight: ultrasound measurement of carotid plaque--patient management, genetic research, and therapy evaluation. Nat Clin Pract Neurol 2006;2:611-9.
7. Haust MD. Reaction patterns of intimal mesenchyme to injury, and repair in atherosclerosis. Adv Exp Med Biol 1974;43:35-57.
8. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol 1977;86:675-84.
9. Spence JD. Ultrasound measurement of carotid plaque: Uses in patient management, genetic research and evaluation of new therapies. Nat Clin Prac Neurol 2006;2:611-9.
10. Spence JD. Point: uses of carotid plaque measurement as a predictor of cardiovascular events. Prev Cardiol 2005;8:118-21.
11. Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid Plaque Area: A Tool for Targeting and Evaluating Vascular Preventive Therapy. Stroke 2002;33:2916-22.
12. Johnsen SH, Mathiesen EB, Joakimsen O et al. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromso Study. Stroke 2007;38:2873-80.
13. Barnett PA, Spence JD, Manuck SB, Jennings JR. Psychological stress and the progression of carotid atherosclerosis. J Hypertension 1997;15:49-55.
14. Spence JD, Hegele RA. Noninvasive phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:e188-e189.
15. Pollex RL, Hegele RA. Genetic determinants of carotid ultrasound traits. Current Atherosclerosis Reports 2006;8:206-15.
16. Johnsen SH, Mathiesen EB, Joakimsen O et al. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromso Study. Stroke. 2007;38:2873-2880.
17. Klein JH, Hegele RA, Hackam DG, Koschinsky ML, Huff MW, Spence JD. Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area. Arterioscler Thromb Vasc Biol 2008;28:1851-6.
18. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26.
19. Schillinger M, Exner M, Mlekusch W et al. Inflammation and Carotid Artery--Risk for Atherosclerosis Study (ICARAS). Circulation 2005;111:2203-9.
20. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-81.
21. Hansson GK. Inflammation, Atherosclerosis, and Coronary Artery Disease. N Engl J Med 2005;252:1685-95.
22. Bobik A, Agrotis A, Kanellakis P et al. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation 1999;99:2883-91.
23. Panutsopulos D, Papalambros E, Sigala F, Zafiropoulos A, Arvanitis DL, Spandidos DA. Protein and mRNA expression levels of VEGF-A and TGF-beta1 in different types of human coronary atherosclerotic lesions. Int J Mol Med 2005;15:603-10.
24. Morsi WG, Shaker OG, Ismail EF et al. HO-1 and VGEF gene expression in human arteries with advanced atherosclerosis. Clin Biochem 2006.
25. Inoue M, Itoh H, Ueda M et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998;98:2108-16.
26. Papalambros E, Sigala F, Georgopoulos S et al. Vascular endothelial growth factor and matrix metalloprote- inase 9 expression in human carotid atherosclerotic plaques: relationship with plaque destabilization via neovascularization. Cerebrovasc Dis 2004;18:160-5.
27. Lee SH, Jeong MH, Bae HR et al. Circulating levels of interleukin-8 and vascular endothelial growth factor in patients with carotid stenosis. J Korean Med Sci 2001;16:198-203.
28. Wang R, Ghahary A, Shen Q, Scott PG, Roy K, Tredget EE. Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. Wound Repair Regen 2000;8:128-37.
29. Bisson MA, McGrouther DA, Mudera V, Grobbelaar AO. The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1. J Hand Surg [Br ] 2003;28:351-6.
30. Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg 1996;98:827-33.
31. Wu Y, Zhang Q, Ann DK et al. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. Am J Physiol Cell Physiol 2004;286:C905-C912.
32. Gira AK, Brown LF, Washington CV, Cohen C, Arbiser JL. Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol 2004;50:850-3.
33. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K. The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg [Am] 1996;21:210-5.
34. Lee TY, Chin GS, Kim WJ, Chau D, Gittes GK, Lon- gaker MT. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg 1999;43:179-84.
35. Bains W. Vasoprotective VEGF as a candidate for prevention of recurrence of fibrotic diseases such as Dupuytren's contracture. Med Hypotheses 2003;60:793-6.
36. Bayat A, Stanley JK, Watson JS, Ferguson MW, Ollier WE. Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGFbetaR) gene polymorphisms and Dupuytren's disease. Br J Plast Surg 2003;56:328-33.
37. Dustan HP. Does keloid pathogenesis hold the key to understanding black/white differences in hypertension severity? Hypertension 1995;26:858-62.
38. Stradner F, Ulreich A, Pfeiffer KP. [Dupuytren's con- tracture as a concomitant disease in diabetes mellitus]. Wien Med Wochenschr 1987;137:89-92.
39. Arkkila PE, Kantola IM, Viikari JS. Dupuytren's disease: association with chronic diabetic complications. J Rheumatol 1997;24:153-9.
40. Fitzgerald AM, Kirkpatrick JJ, Naylor IL. Dupuytren's disease. The way forward? J Hand Surg [Br ] 1999;24:395-9.
41. Berndt A, Kosmehl H, Mandel U et al. TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 1995;27:1014-20.
42. Grotendorst GR, Rahmanie H, Duncan MR. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J 2004;18:469-79.
43. Barbieri SS, Weksler BB. Tobacco smoke cooperates with interleukin-1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. FASEB J. 2007;21:1831-43.
44. Cheon SS, Wei Q, Gurung A et al. Beta-catenin regulates wound size and mediates the effect of TGF-beta in cutaneous healing. FASEB J 2006;20:692-701.
45. Cheon SS, Cheah AY, Turley S et al. beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fi- bromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci SA 2002;99:6973-8.
46. Varallo VM, Gan BS, Seney S et al. Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene 2003;22:3680-4.
47. Khoo YT, Ong CT, Mukhopadhyay A et al. Upregula- tion of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. J Cell Physiol 2006;208:336-43.
48. Cicha I, Yilmaz A, Klein M et al. Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemo- taxis in vitro. Arterioscler Thromb Vasc Biol 2005;25:1008-13.
49. Caraci F, Gili E, Calafiore M et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts The myofibroblast: one function, multiple origins. Pharmacol Res 2008;
50. Hinz B, Phan SH, Tannickal VJ, Galli A, Bochaton- Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007;170:1807-16.
51. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercho- lesterolemia. Atherosclerosis 2008;198:39-48.
52. Ong CT, Khoo YT, Mukhopadhyay A et al. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol 2007;16:394-404.